Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 72%
filed 2026-05-26
Item 8.01
Exzeo announced authorization of a $12 million share repurchase program with a Rule 10b5-1 trading plan effective immediately. While share buybacks are routine capital allocation decisions, the $12 million authorization and formal adoption of a Rule 10b5-1 plan represent a material corporate action that signals management's confidence in valuation and capital deployment strategy. This does not fit neatly into the more specific event categories (not M&A, not compensation, not a departure/appointment), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-05-26
Item 2.02
The filing discloses quarterly financial results for the period ended March 31, 2026, via a press release furnished as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which is material to investors as it provides periodic financial performance information about the registrant.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-26
Item 1.01
BlackRock Monticello Debt REIT entered into a First Amendment to its revolving credit agreement with JPMorgan Chase Bank on May 21, 2026, extending the maturity date to May 20, 2027 and modifying the applicable margin. This refinancing activity materially affects the Company's liquidity and debt obligations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This is a clear disclosure of shareholder voting results from Burlington Stores' annual meeting held May 19, 2026, covering four proposals: election of seven directors, ratification of Deloitte & Touche LLP as auditor, advisory Say-On-Pay vote, and frequency of future Say-On-Pay votes. The filing presents detailed vote tallies for each proposal, which is the core content of Item 5.07 (Submission of Matters to a Vote of Security Holders).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 1.01
Shimmick Corporation entered into an Underwriting Agreement on May 22, 2026, for a public offering of 3,730,000 shares at $3.50 per share, with the underwriter exercising its option to purchase an additional 559,500 shares, resulting in total issuance of 4,289,500 shares and net proceeds of approximately $14.0 million. This is a material equity issuance that dilutes existing shareholders and represents a significant capital raise disclosed under Item 1.01.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-05-26
Item 5.02
The filing discloses adoption of two executive compensation arrangements: the Executive Severance Plan (ESP) establishing severance multiples for named executive officers (Tier I CEO at 3.0x, Tier II NEOs at 1.0-2.0x base salary plus target bonus), and an amended and restated Value Creation Incentive Plan (VCIP) providing cash incentive bonuses based on performance goals. These are compensatory arrangements affecting executive officers and named executives, directly within the scope of Item 5.02(e).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
Callaway Golf held its 2026 Annual Meeting of Shareholders on May 21, 2026, with shareholders voting on three proposals: election of nine directors (including Thomas G. Dundon and Mark D. Mandel), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. All proposals received shareholder approval.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-05-26
Item 7.01
The disclosure concerns an unsolicited tender offer from Zodiac Partners II and the Board's recommendation regarding it. This constitutes a material acquisition or change-of-control activity that would significantly affect investor assessment of the company's future. Tender offers and Board recommendations on potential acquisitions are core M&A events under Item 1.01/2.01 scope, even when disclosed via Item 7.01 Regulation FD.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This is a clear disclosure of shareholder voting results from Viking Therapeutics' 2026 Annual Meeting of Stockholders held on May 19, 2026. The filing reports results on three proposals: election of Class II directors (J. Matthew Singleton and S. Kathryn Rouan, Ph.D.), ratification of CBIZ CPAs P.C. as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies and passage of all three proposals constitute material shareholder actions that affect corporate governance and oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This is a clear disclosure of shareholder vote results from Vera Therapeutics' 2026 Annual Meeting of Stockholders held on May 21, 2026, covering three proposals: election of Class II directors (Morrisey, Enright, Meyers), ratification of KPMG LLP as independent auditor, and advisory approval of executive compensation. The filing presents final voting tallies for each matter, which is the hallmark of Item 5.07 shareholder_vote_results disclosures.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 3.02
Fortress Private Lending Fund sold 431,701 Class I common shares for $10.4 million in aggregate consideration to accredited investors pursuant to Section 4(a)(2) and Regulation D exemptions, diluting existing shareholders and raising capital.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 8.01
The Company disclosed material portfolio and financial metrics as of April 30, 2026, including NAV per Class I share of $24.16, aggregate NAV of approximately $1.1 billion, portfolio fair value of $1.8 billion, $763.8 million in debt outstanding, 88 portfolio companies, and a weighted average yield of 9.8%, along with a monthly distribution declaration of $0.1812 per Class I share.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-05-26
Item 8.01
MasterBrand discloses that the Federal Trade Commission has closed its investigation of the proposed merger with American Woodmark and the Hart-Scott-Rodino waiting period has expired, clearing the way for closing "on or about May 28, 2026." This is a material milestone in the completion of a merger transaction that was entered into on August 5, 2025, and represents a significant corporate event affecting the registrant's future operations and structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from the May 21, 2026 annual meeting of Republic Airways Holdings Inc. The filing reports voting outcomes for three proposals: election of six directors, advisory approval of named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditor. All three proposals passed with substantial majorities, and the detailed vote tallies (For/Against/Abstain/Broker Non-Votes) are presented for each proposal as required by Item 5.07.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-05-26
Item 8.01
American Woodmark discloses that the Federal Trade Commission has closed its investigation and the Hart-Scott-Rodino waiting period has expired for the company's proposed merger with MasterBrand, with closing expected on or about May 28, 2026. This represents a material milestone in the completion of a merger transaction that was entered into on August 5, 2025, and directly impacts the registrant's control and structure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-05-26
Item 5.02
Richard Wohl, Executive Vice President and General Counsel since October 2011, is retiring effective June 5, 2026. While the filing also discloses accelerated vesting of equity awards (~$364,346), the principal disclosed action is the departure of a named executive officer from a senior legal role. The accelerated vesting is a severance-related accommodation rather than the primary event.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 8.01
The filing discloses that exclusivity provisions in a non-binding letter of intent with Terra Quantum have expired, allowing MLAC II to pursue discussions with other potential business combination targets. While this is a development in M&A discussions, it does not constitute entry into, completion of, or termination of a material acquisition or change of control—the letter of intent was non-binding and exclusivity has merely lapsed. The event is material to investors as it affects the likelihood and scope of a potential business combination, but does not fit cleanly into the ma_activity category, which typically covers binding agreements or completed transactions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-05-26
Item 1.01
All In FutureTech Alliance entered into material definitive agreements to acquire approximately 57.67% of HyalRoute Communication Group Limited through a Debt-to-Equity Rights Purchase Agreement (43.55% for $1.742 billion in stock) and two Minority Share Purchase Agreements (14.12% for $564.8 million in stock), with total consideration exceeding $2.3 billion in dilutive equity issuance. The transaction requires shareholder approval and regulatory clearance.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 7.01
The Company announced FDA approval of its ANDA for Gallium Ga-68 gozetotide (PSMA-11), a significant regulatory milestone for a pharmaceutical company. While this is a material event affecting investor assessment of the registrant's product pipeline and commercial prospects, it does not fit neatly into the predefined taxonomy categories (not an earnings release, M&A activity, impairment, or other specific event types). This regulatory approval is best classified as "other_material" given its clear materiality to a pharmaceutical company's business prospects.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-05-26
Item 1.01
This disclosure concerns a First Amendment to an Asset Purchase Agreement dated May 22, 2026, modifying the Company's acquisition of substantially all know-how assets relating to Bio Insights LLC's PanOmics Assay platform for $30 million in Series A Convertible Preferred Stock. While the Amendment primarily deletes the Management Shares provision (12% equity grant to executives), it is filed under Item 1.01 and relates to a material acquisition transaction previously disclosed on April 27, 2026. The $30 million purchase price and strategic nature of the PanOmics Assay assets (NGS multi-omics platform for drug discovery and precision medicine) constitute a material acquisition activity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-05-26
Item 3.01
Columbus Acquisition Corp received written notice from Nasdaq on May 22, 2026, that it failed to comply with two continued listing criteria: the Minimum Holders Rule (requiring 400+ holders) and the Market Value of Listed Securities Rule (requiring $50 million MVLS). While the notices are characterized as deficiency notifications rather than imminent delisting, the Company faces a 45-day deadline to submit a compliance plan for the Minimum Holders Rule and a 180-day compliance period for the MVLS Rule, with explicit warning that failure to regain compliance will result in delisting notification. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Spectral AI announced on May 26, 2026 that the FDA granted De Novo Classification for its DeepView® System, authorizing commercial distribution in the United States. This is a material regulatory milestone that enables the company to commercialize a key product, but it does not fit neatly into the standard 8-K event taxonomy (not an earnings release, M&A activity, executive change, impairment, or other specifically enumerated category). The De Novo pathway is a significant regulatory achievement for a medical device company that would affect investor assessment of commercialization prospects.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 8.01
This Item 8.01 disclosure describes a comprehensive business overview and strategic pivot for Quantum Cyber N.V., including a name change from "Mainz Biomed N.V." to "Quantum Cyber N.V." in April 2026 and formation of a U.S. subsidiary (Quantum Drones Corporation) in May 2026. The filing details a fundamental shift from a pharmaceutical genomics company to an AI and quantum computing-focused autonomous vehicle platform developer. While the prose does not fit neatly into the specific event categories (no M&A completion, no earnings release, no executive change, no covenant breach), the material business transformation and strategic repositioning would affect a reasonable investor's assessment of the registrant's operations, market focus, and risk profile.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This is a clear disclosure of shareholder voting results from the 2026 annual meeting held on May 19, 2026, covering three proposals: election of seven directors, ratification of BDO USA as independent auditor, and advisory vote on named executive officer compensation. The filing presents final vote tallies for each matter, which is the core content of Item 5.07 disclosures and is material to investors assessing board composition and governance outcomes.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-05-26
Item 5.02
Milan Rao's departure as Global Chief Operating Officer and Chief Financial Officer effective May 25, 2026 is the principal disclosed action. The filing centers on his step-down from these senior executive roles, which are material positions affecting financial oversight and operational management. The company's ongoing search for a permanent CFO successor underscores the significance of this departure.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Neuphoria received a material revenue distribution of AUD $1.416M (approximately USD ~$950K) from its participation in the Cancer Therapeutics CRC related to Pfizer's KAT6 program milestone. The company also disclosed it is eligible to receive approximately 4.65% of future milestone payments estimated at USD $460M total across all parties. While this is a revenue/milestone event, it does not fit cleanly into earnings_release (no quarterly/annual results disclosure) or other standard categories, making other_material the most appropriate classification for this passive participation in a third-party licensing arrangement with contingent future payments.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-26
Item 3.03
The Board adopted Amendment No. 1 to reduce the quorum requirement for stockholder meetings from a majority to one-third of shares outstanding, materially modifying stockholder rights and governance dynamics.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-05-26
Item 1.01
Bleichroeder Acquisition Corp. II amended its material merger agreement with Pasqal Holding SAS, modifying the transaction structure through assignment of the merger subsidiary and increasing financing from $200 million to $250 million. The company filed a Form F-4 registration statement in connection with the proposed business combination, which requires shareholder approval.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-05-26
The filing discloses Pre-Paid Purchase #3, a material transaction under Item 1.01 in which Future FinTech issued a Pre-Paid Instrument with a principal amount of $2,160,000 in exchange for $2,000,000 in cash proceeds. This represents a dilutive equity issuance under a pre-paid securities purchase agreement previously approved by shareholders. The transaction is part of a larger $10 million funding facility and involves the issuance of common stock, making it a material capital raise typical of dilutive issuances at smaller-cap companies.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-05-26
Item 7.01
The filing discloses entry into a Business Combination Agreement dated May 25, 2026, between SPAC Axiom Intelligence Acquisition Corp 1 and Terra Quantum AG. The transaction contemplates formation of acquisition entities and mergers resulting in both SPAC and Terra Quantum becoming wholly owned subsidiaries of a new public company (PubCo), constituting a material change of control and business combination. This is a classic SPAC merger transaction with substantial strategic and financial implications.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-05-26
Item 1.01
Toppoint Holdings completed a private placement of 5,000,000 shares of common stock at $0.83 per share for aggregate gross proceeds of $4,150,000, structured as a Securities Purchase Agreement with accredited investors and offshore participants under Section 4(a)(2) and Regulation D Rule 506(b). This unregistered equity issuance materially dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Other material
confidence 68%
filed 2026-05-26
Item 2.03
Rising Dragon Acquisition Corp. issued two $50,000 unsecured promissory notes to its sponsor (Aurora Beacon LLC) and a merger counterparty designee (SZG Limited) on May 15, 2026, to fund the trust account and extend the business combination deadline to June 15, 2026. The notes are convertible into IPO units at $10.00 per unit, combining debt and equity financing elements in support of the SPAC's active merger negotiations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-05-26
Item 1.01
BurTech Acquisition Corp II completed its initial public offering on May 26, 2026, raising $80 million in gross proceeds from the sale of 8 million units at $10.00 per unit, along with entry into multiple material definitive agreements including underwriting, warrant, trust, registration rights, and private placement agreements.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 3.02
BurTech completed an unregistered private placement of 252,000 units at $10.00 per unit for $2.52 million in gross proceeds, with 222,000 units sold to the Sponsor and 30,000 to third-party investors, pursuant to Section 4(a)(2) exemption and occurring simultaneously with the IPO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-26
Item 5.02
Four directors—Shahal M. Khan, Leon Golden, Scott E. Young, and Sergey Alekseev—were appointed to the board of BurTech in connection with the IPO on May 21, 2026, with assignments to key board committees including Audit, Compensation, and Nominating and Corporate Governance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-05-26
Item 3.01
Evolution Metals & Technologies Corp. received a notice from Nasdaq on May 21, 2026, that it failed to comply with Nasdaq Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for the period ended March 31, 2026. Although the Company cured the deficiency by filing the Form 10-Q on May 22, 2026, and regained compliance by May 26, 2026, the initial notice of non-compliance with a continued listing rule constitutes a material delisting risk event.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 2.03
This Item 2.03 disclosure reports the issuance of Consolidated Bonds and Consolidated Discount Notes by the Federal Home Loan Bank of Cincinnati. Schedule A details three specific bond issuances totaling approximately $575.5 million in principal amount across trade dates in May 2026. While Item 2.03 is the designated item for creation of direct financial obligations, the event does not fit neatly into the more specific taxonomy categories (covenant_breach, dilutive_issuance, etc.). The issuance of debt securities is material to investors assessing the registrant's capital structure and financial obligations, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-05-26
Item 2.02
The filing discloses a press release announcing financial results for the fiscal first quarter ended April 30, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard earnings release disclosure, which is material to investors as it provides periodic financial performance information.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-26
Item 2.03
This Item 2.03 disclosure reports the issuance of consolidated obligations (debt securities) totaling approximately $725 million across four tranches on trade date 5/21/2026. While Item 2.03 is nominally for "Creation of a Direct Financial Obligation," the filing itself notes that "although certain aggregated issuances of consolidated obligations are material to the Bank, we have not made a judgment as to the materiality of any particular consolidated obligation or obligations." The disclosure is routine debt issuance reporting for a Federal Home Loan Bank, which regularly issues consolidated obligations as its primary funding mechanism. This does not fit cleanly into covenant_breach (no breach alleged), ma_activity (no acquisition/merger), or other specific event types—it is a material debt issuance that warrants classification as other_material rather than forcing it into an ill-fitting category.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 25%
filed 2026-05-26
Item 2.03
This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) totaling approximately $620 million across four debt instruments with maturities ranging from November 2026 to May 2031. While Item 2.03 is the appropriate disclosure vehicle for new debt obligations, the filing itself does not indicate a covenant breach, acceleration, or triggering event—it is a routine debt issuance disclosure. The low confidence reflects genuine uncertainty about whether this routine debt issuance should be classified as a material event or as "other_material," but covenant_breach is the least appropriate classification given the absence of any breach language.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-26
Item 2.03
The filing discloses the Federal Home Loan Bank of Indianapolis becoming the primary obligor on consolidated obligation bonds totaling $100 million across four tranches with maturities ranging from 2030 to 2041. While Item 2.03 is technically about creation of direct financial obligations, this disclosure does not fit cleanly into the covenant_breach category (no breach alleged) and the bonds appear to be routine consolidated obligations issued by the FHLBank system rather than a triggering event of financial distress. The materiality lies in the new debt obligation itself, but the event type taxonomy lacks a dedicated "debt issuance" category, making "other_material" the most appropriate classification for this material but routine debt financing activity.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 2.03
This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds totaling $500 million ($250M + $250M) by the Federal Home Loan Bank of Dallas. While the filing explicitly states "the Bank has not made a judgment as to the materiality of these consolidated obligation bonds," the issuance of half a billion dollars in debt securities represents a material creation of financial obligations that would affect a reasonable investor's assessment of the registrant's capital structure and leverage. The event does not fit neatly into the more specific taxonomy categories (it is not a covenant breach, going concern, or impairment), making "other_material" the most appropriate classification for this routine but material debt issuance disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
EPAM held its Annual Meeting of Stockholders on April 1, 2026, with stockholders voting on seven matters: election of four Class II directors (Balazs Fejes, Eugene Roman, Jill Smart, Ronald Vargo), approval of charter amendments enabling stockholder-called special meetings, ratification of Deloitte & Touche LLP as independent auditors, an advisory compensation vote, and amendments to the 2025 Long Term Incentive Plan and 2021 Employee Stock Purchase Plan.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 65%
filed 2026-05-26
Item 8.01
The filing announces a special meeting of MHC members scheduled for July 7, 2026, to vote on waiving the MHC's right to receive quarterly dividends up to $1.27 per share over 12 months. While this is technically a notice of a future vote rather than results of a completed vote, the disclosure centers on a shareholder voting event that would materially affect dividend policy and capital allocation. The waiver would allow the Company to retain capital otherwise distributed to the mutual holding company, making this material to investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
CDW stockholders voted at the Annual Meeting held on May 26, 2026, on five proposals: election of nine directors, advisory vote on named executive officer compensation, ratification of Ernst & Young LLP as auditor, approval of a Certificate of Incorporation amendment permitting written consent, and a stockholder proposal on independent board chair requirements. The filing discloses detailed voting tallies including For, Against, Abstentions, and Broker Non-Votes for each proposal.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 8.01
Genprex announced publication of a peer-reviewed abstract at the 2026 ASCO Annual Meeting presenting positive clinical data from its Acclaim trials showing that high Trop-2 and low PTEN biomarkers correlate with prolonged PFS in NSCLC patients receiving Reqorsa gene therapy. While this is clinical validation of a lead drug candidate and biomarker discovery that would be material to investors assessing development progress, it does not fit neatly into the standard 8-K taxonomy—it is neither an earnings release, M&A activity, executive change, restatement, nor other specifically enumerated event. The disclosure represents material clinical progress and biomarker validation that would affect a reasonable investor's assessment of the company's pipeline advancement.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-05-26
Item 5.02
John Brown, Founder and Executive Chairman of Zion Oil & Gas, passed away on May 22, 2026. This constitutes a departure of a named executive officer due to death. The filing explicitly discloses the death of the company's founder and long-serving Executive Chairman, which is material to investors as it represents a significant leadership transition for the organization.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
Smith Micro held its annual stockholder meeting on May 26, 2026, with shareholders voting on eight proposals including director elections, executive compensation approval (say-on-pay), auditor ratification, equity plan amendments, warrant issuance authorizations, and approval of a 1:5 reverse stock split effective June 4, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This Item 5.07 filing discloses the final results of Patriot National Bancorp's 2026 Annual Meeting of Shareholders held on May 20, 2026, including voting outcomes on three proposals: election of seven directors, authorization for a reverse stock split (1-for-10 to 1-for-20 ratio), and ratification of Baker Tilly US, LLP as independent auditor. The reverse stock split authorization is material to investors as it represents a potential significant capital structure change.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-05-26
Item 2.02
The filing discloses Transcat's financial results for fiscal Q4 and year ended March 28, 2026 via a press release (Exhibit 99.1) and accompanying investor slides (Exhibit 99.2) for an earnings conference call. This is a standard earnings release disclosure under Item 2.02, which is material to investors assessing the company's financial performance.
View raw filing on EDGAR →